This article was originally published on The limbic Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented...Continue Reading